Next Issue
Volume 76, May
Previous Issue
Volume 76, January
 
 
arm-logo

Journal Browser

Journal Browser
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Adv. Respir. Med., Volume 76, Issue 2 (April 2008) – 7 articles , Pages 75-124

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
86 KiB  
Review
Cell Phenotype Determines PAI-1 Antiproliferative Effect—Suppressed Proliferation of the Lung Cancer but Not Prostate Cancer Cells
by Joanna Chorostowska-Wynimko, Marta Kędzior, Radosław Struniawski, Paulina Jaguś, Ewa Skrzypczak-Jankun and Jerzy Jankun
Adv. Respir. Med. 2008, 76(2), 101-110; https://doi.org/10.5603/ARM.27919 - 22 Jun 2010
Cited by 1 | Viewed by 291
Abstract
Introduction: Plasminogen inhibitor activator type 1 (PAI-1) is an important regulator of tumor growth and metastasis formation acting directly via specific urokinase complexing or indirectly due to its affinity to vitronectin. We have shown previously that PAI-1 modifies angiogenic activity of endothelial [...] Read more.
Introduction: Plasminogen inhibitor activator type 1 (PAI-1) is an important regulator of tumor growth and metastasis formation acting directly via specific urokinase complexing or indirectly due to its affinity to vitronectin. We have shown previously that PAI-1 modifies angiogenic activity of endothelial cells in a dose-dependent manner but also in close relationship to the cell phenotype. Present study aimed on evaluating the PAI-1 effect on the proliferative activity of lung cancer cells (A549), prostate cancer cells (DU145) as well as endothelial cells (HUVEC). Results: Mutated PAI-1 (1, 10, 100 μg/ml) characterized by the prolonged antifibrinolytic activity (T1/2~7000 h) inhibited proliferation of lung cancer A549 cells in a dose-dependent (p < 0.001) and time-dependent (p < 0.001) manner. No significant effect on the DU145 prostate cancer cells has been observed except of the 72 h cultures with highest PAI-1 concentration (100 μg/ml) (p < 0.001). Proliferative activity of endothelial cells (HUVEC) was affected by 100 μg/ml PAI-1 only, and independent of the culture period (24, 48 and 72 h, p < 0.001). Conclusion: Plasminogen inhibitor activator type 1 modulates cell proliferation via antifibrynolitic mechanizm time- and dose-dependently, however final outcome is strongly affected by the cell phenotype. Full article
150 KiB  
Case Report
Interstitial Pneumonitis in a Patient Treated with Amiodarone—Case Report
by Anna Paczek, Monika Szturmowicz, Elżbieta Wiatr, Barbara Burakowska, Anna Fijałkowska and Adam Torbicki
Adv. Respir. Med. 2008, 76(2), 118-124; https://doi.org/10.5603/ARM.27917 - 28 Apr 2008
Viewed by 267
Abstract
Amiodarone, antiarrhythmic drug of III class is used in patients with supraventricular and ventricular arrhythmias, often with coexisting congestive heart failure. Side effects of amiodarone treatment are observed in approximately 75% of patients. Most dangerous are the symptoms of amiodarone pulmonary toxicity occuring [...] Read more.
Amiodarone, antiarrhythmic drug of III class is used in patients with supraventricular and ventricular arrhythmias, often with coexisting congestive heart failure. Side effects of amiodarone treatment are observed in approximately 75% of patients. Most dangerous are the symptoms of amiodarone pulmonary toxicity occuring in 2–17% of patients. We present a patient with COPD, in whom interstitial pneumonitis with radiologic features of organizing pneumonia developed after one year of amiodaron treatment due to supraventricular and ventricular arrhythmias. The drug was stopped and steroids were introduced due to marked respiratory insufficiency. Regression of pulmonary symptoms and improvement of ventilatory parameters were observed after 3 months of treatment. Pathogenesis, diagnostic procedures and current methods of treatment of this jatrogenic disease are discussed. Full article
202 KiB  
Case Report
Mycobacterial Infection Caused by Mycobacterium avium in Allogenic Bone Marrow Transplant Recipient with Concomittant Bronchiolitis Obliterans as a Manifestation of Graft Versus Host Disease—Case Report and Review of the Literature
by Agnieszka Buraczewska, Anna Kempisty, Jan Kuś and Małgorzata Bartosiewicz
Adv. Respir. Med. 2008, 76(2), 111-117; https://doi.org/10.5603/ARM.27916 - 28 Apr 2008
Viewed by 256
Abstract
Patients after organ transplantations are at risk for mycobacteriosis development. Frequency of the mycobacterial infection after bone marrow transplantation (BMT) is not as high as one could expect. It ranges from 0.4 to 4.9%. We present a case of a female patient after [...] Read more.
Patients after organ transplantations are at risk for mycobacteriosis development. Frequency of the mycobacterial infection after bone marrow transplantation (BMT) is not as high as one could expect. It ranges from 0.4 to 4.9%. We present a case of a female patient after allogenic BMT as a treatment of chronic myelogenous leucaemia, with bronchiolitis obliterans as a symptom of graft versus host disease (GvHD), treated with corticosteroids and infected with Mycobacterium avium. She was admitted to the hospital with dyspnoea, cough with large amount of sputum production and subfebrile status. She had partial respiratory insufficiency and obturative disturbances of respiration (FEV1 0.67 l i.e., 22% of normal) with decline of VC (2.23 l i.e., 64% of normal). The high-resolution computed tomography (HRCT) revealed multifocal infiltrations and bronchiectases in the upper and middle pulmonary fields, which were absent in the previous HRCT taken 3 years earlier. In the bronchial secretion acid-fast bacilli were found by smear and culture. The isolate was classified as Mycobacterium avium complex (MAC) by high performance liquid chromatography (HPLC). The patient was treated with clarithromycin, ciprofloxacin, isoniazide (INH), ethambutol (EMB), amikacin, but M. avium was still present in the sputum after 3 months. Treatment was continued in her parent hospital, where after a few months her sputum became negative for M. avium. But she died over a year later from progressive respiratory insufficiency in the course of bronchiolitis obliterans. The patient was in the group of high risk for mycobacterial infection development and the course of her illness was typical. We decided however to present the case as the topic seems to be quite neglected in the literature. Full article
82 KiB  
Review
Corticosteroid Treatment in Airways Narrowing
by Ryszarda Chazan
Adv. Respir. Med. 2008, 76(2), 96-100; https://doi.org/10.5603/ARM.27918 - 28 Apr 2008
Viewed by 235
Abstract
Corticosteroids (CS) have been used for many years and proved to be the most effective treatment in asthmatic patients. They are controllers of choice in the management of most adult patients with asthma. CS reduce asthma symptoms, improve lung function, reduce frequency of [...] Read more.
Corticosteroids (CS) have been used for many years and proved to be the most effective treatment in asthmatic patients. They are controllers of choice in the management of most adult patients with asthma. CS reduce asthma symptoms, improve lung function, reduce frequency of asthma attacks, hospital admissions and asthma mortality. CS prevent reversible airway narrowing but the effects wane after discontinuing the therapy. CS inhibit the synthesis of many cytokines involved in asthmatic inflammation. They suppress inflammation but do not cure underlying cause. The choice of inhaled steroid depends on their pharmacologic properties (receptor affinity and systemic bioavailability). There is no convincing evidence that regular use of combination of inhaled corticosteroid and long acting-β-agonists (LABA) provides any additional benefit in patients with mild asthma. It seems that the optimal management of mild asthma is occasional use of combined therapy when symptoms are present. Long-term combined therapy with inhaled corticosteroid and LABA is still a "golden standard" in patients with moderate and severe asthma. Corticosteroids are also used in chronic obstructive pulmonary disease (COPD) patients. Medication with CS can reduce symptoms but does not alter the course or progression of COPD. There is no effect of corticosteroids on all cause mortality in COPD patients. No suppression of inflammation was found in COPD patients treated with inhaled and oral corticosteroids, even at high doses. There is a small beneficial effect of CS against acute exacerbations in patients with severe disease, with improved clinical outcome and reduced length of hospital admission. Combination inhalers that include a LABA and CS are more effective then either component alone. Full article
314 KiB  
Article
Is Body Mass Index Associated with Asthma in Children?
by Anna Szroniak, Izabela Łabędzka, Anna Bręborowicz and Marek Niedziela
Adv. Respir. Med. 2008, 76(2), 88-95; https://doi.org/10.5603/ARM.27915 - 28 Apr 2008
Viewed by 272
Abstract
Introduction: Asthma is a disease with a complex pathogenesis. Obesity seems to be crucial risk factor for the development and worse clinical outcome of the disease. The aim of the study was to assess the relation between the body weight and the [...] Read more.
Introduction: Asthma is a disease with a complex pathogenesis. Obesity seems to be crucial risk factor for the development and worse clinical outcome of the disease. The aim of the study was to assess the relation between the body weight and the severity of asthma and preliminary analysis of factors influencing nutritional status among asthmatic children. Material and methods: Complete data have been available for 101 children with mild persistent, moderate persistent and severe persistent asthma. The questionnaires have been completed according to the physical and spirometric examination, analysis of medical documentation and anamnesis. Weight and height were measured in all children. To estimate the body mass index (BMI) values we used Body Mass Index Percentile Charts for Age. The control group consisted of 45 healthy school children. Results: Mean BMI percentile for age in asthmatic children did not significantly differ from healthy children (53.4 ± 32.3 and 59.5 ± 30.5 respectively). Higher BMI percentiles for the age were observed among boys in comparison to girls (p = 0.018). We did not find statistically significant relation between values of BMI percentiles and severity of asthma, although higher BMI values in boys with severe persistent asthma were noticed. Body mass index percentiles did not correlate with time of treatment and the doses of inhaled corticosteroids. Food allergy and atopic dermatitis in the past influenced BMI values. Conclusions: Mean BMI percentile for age in asthmatic children did not significantly differ from healthy children. The correlation between BMI values and severity of asthma and treatment with inhaled corticosteroids were not found. Full article
85 KiB  
Article
The Coexistence of the Impaired Exercise Tolerance in Patients with Obstructive Sleep Apnea with Gastroesophageal Reflux
by Iwona Hawryłkiewicz, Dariusz Dziedzic, Robert Pływaczewski and Dorota Górecka
Adv. Respir. Med. 2008, 76(2), 83-87; https://doi.org/10.5603/ARM.27914 - 28 Apr 2008
Viewed by 278
Abstract
Introduction: Gastroesophageal reflux (GERD) is a frequent disease in patients with obstructive sleep apnea (OSA). The aim of the study was to evaluate possible correlation between the impairement of exercise tolerance and GERD. Material and methods: We examined 18 patients with [...] Read more.
Introduction: Gastroesophageal reflux (GERD) is a frequent disease in patients with obstructive sleep apnea (OSA). The aim of the study was to evaluate possible correlation between the impairement of exercise tolerance and GERD. Material and methods: We examined 18 patients with OSA, mean AHI—44 ± 22; 6 females, 12 males, mean age 55 ± 9 years. All patients were treated for metabolic disorders and for hypertension or coronary artery disease. In all patients gastroscopy was performed with 24h pHmetry and 6MWT. Results: In 12 patients GERD was found, in 14 patients esophagitis was diagnosed (among them there were 3 patients without GERD). Patients with GERD were younger (53 ± 7 vs. 59 ± 11 years) and more obese (BMI—38 ± 5 vs. 36 ± 9 kg/m2). During 6MWT the distance covered was shorter (in % of normal values) in GERD subjects: 78 ± 17 vs. 86 ± 22%) and desaturation was deeper (91 ± 3 vs. 94 ± 3%). Conclusions: Despite some tendencies the relationship between GERD and impairement of exercise tolerance in OSA patients was not statistically significant. Perhaps study in larger group of subjects will be more reliable. Full article
102 KiB  
Article
Six-Minute Walk Test in Obstructive Sleep Apnoea
by Robert Pływaczewski, Anna Stokłosa, Przemysław Bieleń, Michał Bednarek, Justyna Czerniawska, Luiza Jonczak, Dorota Górecka and Paweł Śliwiński
Adv. Respir. Med. 2008, 76(2), 75-82; https://doi.org/10.5603/ARM.27913 - 28 Apr 2008
Cited by 4 | Viewed by 299
Abstract
Introduction: The aim of this study was to assess results of 6MWT in non-selected group of obstructive sleep apnoea (OSA) patients. In healthy adult subjects 6-minute walking distance (6MWD) range from 400 to 700 m. Obesity, the main symptom of OSA, is [...] Read more.
Introduction: The aim of this study was to assess results of 6MWT in non-selected group of obstructive sleep apnoea (OSA) patients. In healthy adult subjects 6-minute walking distance (6MWD) range from 400 to 700 m. Obesity, the main symptom of OSA, is one of the factors associated with reduction of 6MWD (another common factors: older age, shorter height, female sex, pulmonary, cardiovascular and musculoskeletal diseases). Material and methods: Subjects completed sleep questionnaire and Epworth sleepiness scale before sleep studies (full polysomnography [PSG] or PolyMesam study [PM]). Consecutive OSA subjects (AHI/RDI >10, Epworth score > 9 points) were evaluated. The 6MWT, chest X-ray, spirometry, arterial blood gases, ECG, blood morphology and biochemistry were performed during trial treatment with autoCPAP. Results: We studied 151 subjects (119 males—78.8% and 32 females—21.2%), mean age 53.4 ± 10.5 years. Subjects were obese—BMI = 35.7 ± 6.2 kg/m2 and presented severe OSA—AHI/RDI = 42.4 ± 23.2. To assess relations between 6MWD and AHI/RDI, BMI, age and concomitant diseases we divided subjects in two groups: 1st with 6MWD ≥ lower limit of normal (LLN) (123 pts; 81.5%) and 2nd with 6MWD < LLN (28 pts; 18.5%). Significant differences between groups were found for BMI, FVC (% of predicted) and Borg dyspnea scale before and after 6MWT. In multiple linear regression analysis we found significant correlation between 6MWD and BMI (β = 0.41, p < 0.0001) and arterial hypertension (β = –0.16, p = 0.04). Females had significantly shorter 6MWD than males (401.1 ± 83.6 m and 451.8 ± 107 m, respectively; p = 0.01). Difference was significant after adjustment for BMI and age (analysis of covariance)—R = 0.61, R2 = 0.38 (p < 0.0001). Conclusions: BMI, female sex, arterial hypertension and lower FVC (% of predicted) were related to shorter 6-minute walking distance in OSA patients. Full article
Previous Issue
Next Issue
Back to TopTop